MAPK3 Antibody
- Known as:
- MAPK3 Antibody
- Catalog number:
- 32027
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- MAPK3 Antibody
Related genes to: MAPK3 Antibody
- Gene:
- MAPK3 NIH gene
- Name:
- mitogen-activated protein kinase 3
- Previous symbol:
- PRKM3
- Synonyms:
- ERK1, p44mapk, p44erk1
- Chromosome:
- 16p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-05
- Date modifiied:
- 2015-09-03
Related products to: MAPK3 Antibody
Related articles to: MAPK3 Antibody
- Ginseng dripping pills (GDPs), a traditional Chinese patent medicine, are extensively used for cardiovascular diseases (CVDs), but their active components and underlying mechanisms remain unclear. This study aimed to identify the chemical constituents of GDP and to explore their potential mechanisms in treating myocardial infarction (MI) and atherosclerosis (AS). Chemical profiling was performed using ultra-high-performance liquid chromatography coupled with Q-Exactive hybrid quadrupole-Orbitrap mass spectrometry (UHPLC-Q-Orbitrap MS) and the Global Natural Products Social Molecular Networking (GNPS), leading to the identification of 113 compounds, and 13 blood-absorbed components were identified, with ginsenosides identified as the predominant bioactive constituents. Network pharmacology was then used to predict the key therapeutic targets and associated signaling pathways, and a comprehensive "GDP-component-target-pathway" interaction network was constructed. 18 targets were identified as core targets of GDP in treating CVD. The main pathways involved included PI3K-Akt, RAS, cAMP, Rap1, and calcium signaling. Molecular docking showed that 13 blood-absorbed components of GDP, including ginsenoside Ro, ginsenoside Rs1 and ginsenoside Ra3, had strong binding affinities with MAPK3, MMP9, and PTGS2. These findings suggest that GDP may exert cardioprotective effects through a multicomponent, multitarget, and multipathway mode of action, providing a scientific basis for its clinical application in CVD treatment. - Source: PubMed
Publication date: 2026/09/28
Xu MinglinMao JunyiWang XiangnanJiang JinpingOcholi Simon SaniWang ChaoyangWang YueYu HonghaiHan Lifeng - Gegen Qinlian Decoction (GQD) has shown preclinical antidepressant-like effects, but the disease-relevant signalling architecture of its putative targets remains unclear. - Source: PubMed
Publication date: 2026/09/23
Gao ZixiangLi XiangZhou XianqiZhou ZixuanLi Zining - Xiaoyaosan (XYS) has significant anti-inflammatory effects and is widely used for treating depression. However, the multitarget mechanism of XYS in the treatment of bipolar disorder (BD) remains unexplored. In this study, network pharmacology, molecular docking, and experimental validation were integrated to elucidate the mechanisms of XYS and its therapeutic efficacy in BD. - Source: PubMed
Chen ManDing NanaQiu XingminLi LanGuo YaliWang RongyanqiMo XiaoweiZou TanYu ShangzhenLi XiaojuanChen Jiaxu - : Primary dysmenorrhea (PD) is a prevalent gynecological condition that significantly compromises the quality of life in adolescents and women of reproductive age. Within traditional Chinese medicine (TCM), Cold Coagulation and Blood Stasis Primary Dysmenorrhea (CCBS-PD) represents the most frequently observed syndrome pattern of PD. Wenjing Decoction (WJD), a classical TCM formulation, has been extensively employed for the treatment of CCBS-PD. However, given the multi-component and complex nature of WJD, the potential mechanisms underpinning its therapeutic effect have yet to be elucidated. : A rat model of CCBS-PD was induced through ice-water bath stimulation in conjunction with estradiol benzoate and oxytocin. The pharmacological effects of WJD were evaluated by writhing response, hemorheological parameters, uterine index, histopathological examination, and biochemical assays. Serum-exposed constituents of WJD were characterized using UPLC-Orbitrap Exploris 120 MS. To study the mechanisms of WJD, methods from network pharmacology, molecular docking, and off-target metabolomics were used. Western blot analysis examined representative proteins in the signaling pathways predicted by network pharmacology. Network pharmacology and metabolomics were integrated to construct a pathway-metabolite-target-compound network, and representative targets were analyzed by RT-qPCR. : WJD treatment reduced writhing responses, improved hemorheological abnormalities, and alleviated uterine pathological changes in CCBS-PD rats. Serum pharmacochemistry identified 62 WJD-derived constituents. Metabolomics analysis indicated that WJD was associated with alterations in nitrogen metabolism, valine/leucine/isoleucine biosynthesis and arginine biosynthesis. Network pharmacology and molecular docking suggested several candidate compounds and targets, including Robinetin, Levistolide A, Pratol, 7,4'-dihydroxyflavone, EGFR, AKT1, ESR1, MMP9, MAPK3, and TNF. RT-qPCR showed that selected genes, including AKT1, EGFR, MAPK3, TNF, ESR1, MMP9 and CASP3, were changed in the model group and partially restored following WJD improvement. Western blot analysis demonstrated that WJD treatment decreased the phosphorylation levels of AKT, ERK1/2, and NF-κB, and down-regulated the protein expression of COX-2. : WJD showed beneficial effects in a CCBS-PD rat model. Synthesized assessments indicate a potential link to the actions of serum-exposed constituents, alterations in amino acid metabolism, and modulation of inflammation-related signaling pathways. This research offers initial indications suggesting the multi-component and multi-target pharmacological actions of WJD, although the underlying mechanisms remain to be validated through targeted metabolomics and functional studies. - Source: PubMed
Publication date: 2026/09/01
Li JungeLiu YuxinShao XinZhang YuanluQiu ZhidongWang YongchunQi FeiranTang QiuzhuJia Ailing - Myocardin-related transcription factor B (MRTFB) acts as a transcriptional coactivator for serum response factor (SRF) and regulates actin cytoskeletal dynamics. Despite its biological significance, the phosphoregulatory network, upstream kinases, and interactors remain poorly understood. To explore this, we analyzed global phosphoproteomic datasets to identify predominant phosphosites. We categorized phosphosites in other proteins as positively or negatively co-regulated with the predominant phosphosites of MRTFB and also integrated predicted upstream kinases and interactors of MRTFB. Further, phosphosite conservation, co-occurrence patterns, and functional and pathway enrichment analyses of co-regulated proteins were also performed. We identified S66 and S921 as predominant phosphosites in MRTFB, with the highest detection frequency across multiple experimental conditions. These phosphosites were found to be conserved within the MRTF family and across multiple species. From the predicted upstream kinases, MAPK1, MAPK3, MAST3, and CSNK1A1 were identified as predicted upstream kinases. Co-occurrence analysis revealed high positive co-occurrence between the predominant phosphosites, S66 and S921, suggesting similar functional roles. Functional enrichment analysis highlighted the involvement of co-regulated proteins in the actin cytoskeleton pathway. This study provides the detailed phosphoproteomic landscape of MRTFB, mapping its upstream kinases and co-regulated proteins involved in actin cytoskeleton regulation. - Source: PubMed
Publication date: 2026/09/05
John JetnaGopalakrishnan VaishnaviSubair SuhailGopalakrishnan Athira PerunellyPalollathil AkhinaRaju Rajesh